e-Article
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 6/10/2023 Supplement17, Vol. 41, pLBA4619-LBA4619, 1p
Subject
Language
ISSN
0732183X